PACIRA BIOSCIENCES INC (PCRX)
US6951271005 - Common Stock
We assign a fundamental rating of 6 out of 10 to PCRX. PCRX was compared to 198 industry peers in the Pharmaceuticals industry. PCRX scores excellent on profitability, but there are some minor concerns on its financial health. PCRX may be a bit undervalued, certainly considering the very reasonable score on growth These ratings could make PCRX a good candidate for value investing.
1. Profitability
1.1 Basic Checks
In the past year PCRX was profitable.
PCRX had a positive operating cash flow in the past year.
PCRX had positive earnings in 4 of the past 5 years.
In the past 5 years PCRX always reported a positive cash flow from operatings.
1.2 Ratios
With an excellent Return On Assets value of 2.67%, PCRX belongs to the best of the industry, outperforming 88.21% of the companies in the same industry.
PCRX's Return On Equity of 4.83% is amongst the best of the industry. PCRX outperforms 88.21% of its industry peers.
PCRX has a Return On Invested Capital of 4.02%. This is amongst the best in the industry. PCRX outperforms 83.08% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for PCRX is significantly below the industry average of 16.31%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.67% | ||
| ROE | 4.83% | ||
| ROIC | 4.02% |
ROA(3y)1.88%
ROA(5y)3.15%
ROE(3y)4.21%
ROE(5y)6.6%
ROIC(3y)4.32%
ROIC(5y)4.07%
1.3 Margins
PCRX's Profit Margin of 6.23% is amongst the best of the industry. PCRX outperforms 86.67% of its industry peers.
In the last couple of years the Profit Margin of PCRX has declined.
PCRX has a Operating Margin of 12.94%. This is amongst the best in the industry. PCRX outperforms 86.15% of its industry peers.
PCRX's Operating Margin has improved in the last couple of years.
PCRX has a Gross Margin of 72.65%. This is in the better half of the industry: PCRX outperforms 78.46% of its industry peers.
In the last couple of years the Gross Margin of PCRX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.94% | ||
| PM (TTM) | 6.23% | ||
| GM | 72.65% |
OM growth 3Y-2.79%
OM growth 5Y20.05%
PM growth 3Y-43.17%
PM growth 5YN/A
GM growth 3Y-0.03%
GM growth 5Y-0.43%
2. Health
2.1 Basic Checks
PCRX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
PCRX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for PCRX has been increased compared to 5 years ago.
The debt/assets ratio for PCRX has been reduced compared to a year ago.
2.2 Solvency
PCRX has an Altman-Z score of 1.88. This is not the best score and indicates that PCRX is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 1.88, PCRX is in the better half of the industry, outperforming 70.26% of the companies in the same industry.
PCRX has a debt to FCF ratio of 3.75. This is a good value and a sign of high solvency as PCRX would need 3.75 years to pay back of all of its debts.
PCRX has a Debt to FCF ratio of 3.75. This is amongst the best in the industry. PCRX outperforms 89.23% of its industry peers.
A Debt/Equity ratio of 0.59 indicates that PCRX is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.59, PCRX is not doing good in the industry: 64.62% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.59 | ||
| Debt/FCF | 3.75 | ||
| Altman-Z | 1.88 |
ROIC/WACC0.52
WACC7.75%
2.3 Liquidity
PCRX has a Current Ratio of 5.24. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.
PCRX's Current ratio of 5.24 is fine compared to the rest of the industry. PCRX outperforms 68.21% of its industry peers.
PCRX has a Quick Ratio of 4.17. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 4.17, PCRX is doing good in the industry, outperforming 61.03% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.24 | ||
| Quick Ratio | 4.17 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 12.74% over the past year.
PCRX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 22.93% yearly.
Looking at the last year, PCRX shows a small growth in Revenue. The Revenue has grown by 1.21% in the last year.
The Revenue has been growing by 14.88% on average over the past years. This is quite good.
EPS 1Y (TTM)12.74%
EPS 3Y9.9%
EPS 5Y22.93%
EPS growth Q2Q11.25%
Revenue 1Y (TTM)1.21%
Revenue growth 3Y16.25%
Revenue growth 5Y14.88%
Revenue growth Q2Q5.37%
3.2 Future
PCRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.68% yearly.
Based on estimates for the next years, PCRX will show a quite strong growth in Revenue. The Revenue will grow by 8.36% on average per year.
EPS Next Y-2.82%
EPS Next 2Y11.46%
EPS Next 3Y14.4%
EPS Next 5Y13.68%
Revenue Next Year2.34%
Revenue Next 2Y6.04%
Revenue Next 3Y7.08%
Revenue Next 5Y8.36%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
PCRX is valuated reasonably with a Price/Earnings ratio of 10.11.
93.33% of the companies in the same industry are more expensive than PCRX, based on the Price/Earnings ratio.
PCRX is valuated cheaply when we compare the Price/Earnings ratio to 28.11, which is the current average of the S&P500 Index.
PCRX is valuated reasonably with a Price/Forward Earnings ratio of 10.40.
PCRX's Price/Forward Earnings ratio is rather cheap when compared to the industry. PCRX is cheaper than 93.33% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of PCRX to the average of the S&P500 Index (20.39), we can say PCRX is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.11 | ||
| Fwd PE | 10.4 |
4.2 Price Multiples
90.77% of the companies in the same industry are more expensive than PCRX, based on the Enterprise Value to EBITDA ratio.
PCRX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. PCRX is cheaper than 92.31% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.84 | ||
| EV/EBITDA | 8.3 |
4.3 Compensation for Growth
PCRX has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as PCRX's earnings are expected to grow with 14.40% in the coming years.
PEG (NY)N/A
PEG (5Y)0.44
EPS Next 2Y11.46%
EPS Next 3Y14.4%
5. Dividend
5.1 Amount
No dividends for PCRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PACIRA BIOSCIENCES INC
NASDAQ:PCRX (5/8/2024, 8:34:05 AM)
29.51
+3 (+11.32%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.37B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.11 | ||
| Fwd PE | 10.4 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)0.44
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.67% | ||
| ROE | 4.83% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 12.94% | ||
| PM (TTM) | 6.23% | ||
| GM | 72.65% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.59 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.24 | ||
| Quick Ratio | 4.17 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)12.74%
EPS 3Y9.9%
EPS 5Y
EPS growth Q2Q
EPS Next Y-2.82%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)1.21%
Revenue growth 3Y16.25%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y